

The Bulletin

This monthly bulletin includes recent changes to our medical policies and reimbursement policies. It is a supplement to our bimonthly provider newsletter, [The Connection](#). **Note:** Medication and dental policy updates are published in *The Connection*.

Our provider website includes [monthly summaries of changes](#) to our reimbursement, medication and dental policies, pre-authorization requirements, *Administrative Manual* and programs or initiatives that impact your office.

Medical policies

Disclaimer: View the [terms and conditions](#) of using our *Medical Policy Manual*.

Commercial

Changes effective October 1, 2022

Durable Medical Equipment

- Negative Pressure Wound Therapy in the Outpatient Setting (#42)
 - Moved the required comprehensive wound care components to the criteria without change to intent; components were previously listed in the Policy Guidelines section

Changes effective November 1, 2022

Behavioral Health

- Eating Disorder Inpatient Treatment (#25)
 - Revised criteria regarding provider types, family therapy for adults, and staff overseeing programming
- Eating Disorder Intensive Outpatient (#26)
 - Revised criteria regarding provider types, family therapy for adults, psychiatric evaluation for intensive outpatient programs, and staff overseeing programming
- Eating Disorder Partial Hospitalization (#27)
 - Revised criteria regarding provider types, family therapy for adults, and staff overseeing programming
- Eating Disorder Residential Treatment (#28)
 - Revised criteria regarding provider types, family therapy for adults, and staff overseeing programming

- Psychiatric Inpatient Hospitalization (#29)
 - Revised criteria regarding provider types and family therapy for adults
- Psychiatric Intensive Outpatient (#30)
 - Revised criteria regarding provider types, family therapy for adults, and psychiatric evaluation for intensive outpatient programs
- Psychiatric Partial Hospitalization (#31)
 - Revised criteria regarding provider types and family therapy for adults
- Psychiatric Residential Treatment (#32)
 - Revised criteria regarding provider types and family therapy for adults

Medicare Advantage

Changes effective October 1, 2022

Surgery

- Ventricular Assist Devices and Total Artificial Hearts (#M52)
 - Updated policy with respect to retired national coverage determination (NCD) 20.9 for Artificial Hearts and Related Devices; policy will now redirect indications previously addressed by NCD 20.9 to the *Ventricular Assist Devices and Total Artificial Hearts (#52)* commercial medical policy

Changes effective November 1, 2022

Surgery

- Transcatheter Heart Valve Procedures (#M221)
 - Updated policy to note the Centers for Medicare & Medicaid Services- (CMS-) approved investigational device exemption (IDE) study for the Tendyne transcatheter mitral valve system
 - Updated policy to reflect the revised terminology and coverage criteria in accordance with the updated NCD for transcatheter mitral valve repair (TMVR), now termed mitral valve transcatheter edge-to-edge repair (TEER)

Join our medical policy discussion

We welcome your input and feedback as we draft our medical policies. [Join our email reviewer list](#). While we prefer to receive input as policies are developed, we also have a formal process that allows you to submit additional information, such as clinical trial results, that may warrant a policy review.

Recent updates and archived medical policies

[Recent updates and archived medical policies](#) may include revisions that will be published in the next issue of *The Bulletin*.

Reimbursement policies

Disclaimer: View the [terms and conditions](#) of using our *Reimbursement Policy Manual*.

Commercial

Changes effective February 1, 2023

Administrative

- Timely Receipt of Records (#145)
 - New reimbursement policy stating the following about requested records:
 - Must be received for a claim to be processed
 - Should be returned by the requested date or within 10 days
 - Should be submitted using the method in which the request was sent (e.g., Availity Essentials, fax, etc.)
 - Failure to provide within 45 days will result in member notification for the sake of transparency
 - Failure to provide within 90 days will result in claims denial

Medicine

- Cellular and Gene Therapy Products (#112)
 - Updating the brand name to Skysona for elivaldogene autotemcel, which has been approved by the U.S. Food and Drug Administration (FDA)
 - Revising or adding estimated FDA-approval dates for eladocogene exuparvovec, etranacogene dezaparvovec and omidubicel
 - Adding the following drugs to the Gene Therapies section of Appendix 1 pending FDA approval:
 - beremagene geperpavec (Vyjuvek)
 - exagamlogene autotemcel
 - lovotibeglogene autotemcel
 - lifileucel

Medicare Advantage

Changes effective November 1, 2022

Administrative

- Chiropractic and Osteopathic Treatments (#138)
 - New Medicare Advantage reimbursement policy will largely follow commercial medical policy with the following exceptions:
 - Clarified that CPT 98943 and 97140 may be billed for chiropractic treatment "when benefits apply"
 - Stated that HCPCS S8990 for osteopathic treatment is a Medicare exclusion

Join our reimbursement policy discussion

Comments from physicians and other health care professionals regarding reimbursement policies are welcome. If you have a comment regarding a reimbursement policy, please complete the [Reimbursement Policy Feedback Form](#).

Verify your provider information

Providing up-to-date and accurate information about the providers in each of our networks is critical for our members to access care and a compliance requirement for the Affordable Care Act (ACA) and Medicare Advantage plans.

Validating provider directory content

Please [follow these steps](#) to review the information about your practice every 90 days. **Please respond timely to any requests from us for verification of your directory data.**

If your clinic or facility submits provider rosters to us, please submit changes, corrections, additions or terminations immediately so we can update our directories as soon as possible. **Your roster must be validated and reviewed in its entirety at least once per quarter.**

We appreciate your assistance in keeping information about your practice up to date.

[Subscribe](#) | [Unsubscribe](#) | [Update preferences](#) | [Online privacy and security](#)

© 2022 Asuris P.O. Box 91130 Seattle, WA, 98111-9230, USA